NextCure, Inc.
NextCure, Inc. (NXTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nxtc-20260806xex99d1.htm EX-99.1 Exhibit 99.1 NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results – Announced Proposed Merger with Avere Therapeutics – Preserving Capital in Support of Merger Closing; Continuing Clinical Transition and
ADAR1 Capital Management, LLC purchased 329,153 indirectly-held shares of NextCure, Inc. (NXTC) at an average of $4.93 ($4.80–$5.00, $1.62M total) across 9 trades over 2026-07-30 to 2026-07-31.
ADAR1 Capital Management, LLC purchased 17,608 indirectly-held shares of NextCure, Inc. (NXTC) at an average of $4.98 ($4.95–$5.00) across 4 trades over 2026-07-27 to 2026-07-29.
Over the past 7 days, alphai's AI scored 1 news story mentioning NXTC (NextCure, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent NXTC coverage spans mergers & acquisitions, insider activity and corporate actions.
In the last 30 days, NXTC insiders filed 13 SEC Form 4 transactions — 13 purchases ($1.7M) and no sales. The most active reporter was ADAR1 Capital Management, LLC with 13 filings.
NXTC is trading as a merger vehicle with shrinking cash, restructuring charges, and a planned transition of key programs.
The filing signals continued insider-aligned accumulation, but it is not a fundamental catalyst like earnings or guidance.
This is an insider ownership increase by a 10% owner via indirect holdings, but it is not a new operational or financial catalyst.
M&A headline and merger terms can drive continued momentum and volatility into deal-close expectations.
Deal terms and financing are likely the primary driver of NXTC’s extreme move, with near-term trading focused on merger mechanics and dilution/convertible overhang.
alphai scores every news story that mentions NXTC with an AI model for sentiment and relevance, and aggregates insider trades from NextCure, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
NextCure, Inc. (NXTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nxtc-20260806xex99d1.htm EX-99.1 Exhibit 99.1 NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results – Announced Proposed Merger with Avere Therapeutics – Preserving Capital in Support of Merger Closing; Continuing Clinical Transition and
6 min readADAR1 Capital Management, LLC purchased 329,153 indirectly-held shares of NextCure, Inc. (NXTC) at an average of $4.93 ($4.80–$5.00, $1.62M total) across 9 trades over 2026-07-30 to 2026-07-31.
2 min readADAR1 Capital Management, LLC purchased 17,608 indirectly-held shares of NextCure, Inc. (NXTC) at an average of $4.98 ($4.95–$5.00) across 4 trades over 2026-07-27 to 2026-07-29.
2 min readBiotech stocks rose Tuesday. NextCure (NXTC) jumped over 200% on a definitive all-stock merger with Avere Therapeutics, expected to close in 2H 2026, with the combined firm trading as AVRX. Basel Medical (BMGL) gained 26% after regaining Nasdaq bid-price compliance. Outlook Therapeutics (OTLK) rose 11% ahead of an FDA decision on July 29, 2026. Other gainers included DYAI, NUWE, ATAI, and QNCX.
2 min readNextCure (NASDAQ:NXTC) agreed to merge with Avere Therapeutics, forming Avere Therapeutics on Nasdaq as AVRX. The deal targets development of AVR-001, a once-weekly oral IL-23 therapy. Financing totals $320M, including $251M convertible notes. Proceeds fund Phase 2b/3 psoriasis and Phase 2b ulcerative colitis trials. NXTC shares rose 198.63% to $6.51.
4 min readNextCure, Inc. (NXTC) shares rose about 217% after it agreed to merge with privately held Avere Therapeutics in an all-stock deal. NextCure also announced a concurrent $320 million private placement to fund Avere’s lead inflammatory disease therapy. NXTC was quoted at $6.90, up $4.72, after a prior close of $2.18.
1 min readNextCure (NXTC) agreed to an all-stock merger with private Avere Therapeutics to form Avere Therapeutics, expected to close in 2H 2026. The combined firm will trade on Nasdaq as AVRX. Avere’s lead oral IL-23 antagonist AVR-001 is in Phase 1b. Financing includes a $320M private placement with $251M convertible notes, aimed to fund psoriasis Phase 2b and Phase 3 start, plus ulcerative colitis Phase 2b.
5 min readNextCure, Inc. (NXTC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 tm2620428d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: Avere Therapeutics, Inc.; NEPTUNE MERGER SUB CORP.; NEPTUNE SECOND MERGER SUB, LLC; and NextCure, Inc. Dated as of July 14, 2026 TABLE OF CONTENTS Page
2 min readNextCure (Nasdaq: NXTC) and private Avere Therapeutics announced a definitive all-stock merger to advance Avere’s once-weekly oral IL-23 therapy AVR-001. A $320M private placement includes $251M convertible notes. The combined company will trade on Nasdaq as AVRX under Avere’s name, expected to close H2 2026.
7 min readNextCure, Inc. (NXTC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 nxtc-20260618xex10d1.htm EX-10.1 Exhibit 10.1 NEXTCURE, INC. AMENDED AND RESTATED 2019 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS Page 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 9 3.1 Committee . 9 3.1.1 Powers and Authoritie
2 min read
